Iloprost Concentration-Dependently Attenuates Platelet Function and Apoptosis by Elevating PKA Activity.

Area of Science:

• Pharmacology
• Hematology
• Cell Biology

Background:

• Iloprost is a prostacyclin (PGI2) analogue that activates the IP receptor (PTGIR).
• Elevated cyclic adenosine monophosphate (cAMP) levels regulate various cellular activities.
• Understanding Iloprost's effects on platelet function and apoptosis is crucial.

Purpose of the Study:

• To evaluate the effects of Iloprost on platelet function, apoptosis, hemostasis, and thrombosis.
• To elucidate the underlying molecular mechanisms of Iloprost's actions.
• To investigate Iloprost's therapeutic potential in immune thrombocytopenia (ITP).

Main Methods:

• In vitro assays measuring platelet activation markers (P-selectin, integrin αIIbβ3), aggregation, ATP release, spreading, and clot retraction.
• In vivo studies using FeCl3-induced mesenteric arteriole thrombosis and tail bleeding time in mice.
• Assessment of platelet apoptosis markers (mitochondrial membrane potential, phosphatidylserine externalization).
• Measurement of protein kinase A (PKA) activity, cytoplasmic Ca2+ levels, and caspase-3 activity.

Main Results:

• Iloprost inhibited platelet activation and aggregation concentration-dependently.
• Iloprost reduced platelet apoptosis by inhibiting mitochondrial depolarization and phosphatidylserine externalization.
• Moderate Iloprost doses impaired in vivo hemostasis and thrombosis.
• Low Iloprost doses increased peripheral platelet counts in a mouse model of ITP by inhibiting apoptosis.
• Iloprost elevated PKA activity, suppressed cytoplasmic Ca2+ increase, and inhibited pro-apoptotic signaling.

Conclusions:

• Iloprost dose-dependently inhibits platelet function and apoptosis via PKA activation.
• Moderate Iloprost doses impair hemostasis and thrombosis by suppressing platelet function.
• Low-dose Iloprost enhances platelet counts in ITP by inhibiting apoptosis without affecting platelet function.